Objective: To study the safety and immunogenicity of the measles-mumps-rubella combined vaccine (MMR) produced by Beijing Biological Product Institute.
Methods: Children aged 10-12 years, 2-2.5 years and 8-12 months were selected to be vaccinated with Beijing MMR vaccine (test vaccine). Other groups of children with similar nature were vaccinated with measles vaccine, mumps vaccine and rubella vaccine while using imported MMR vaccine (control vaccine) as controls.
Results: The safety of the Beijing MMR vaccine was confirmed after vaccinating 32 children above 2 years old. Among 104 children of 8-12 months were vaccinated with Beijing MMR vaccine, only 6.7% of the children had transient fever and 1.9% had signs of rashes but with no other signs observed. The positive seroconversion rates of measles, rubella and mumps anti-HI were 100%, 100% and 85.7% respectively. GMT also showed high lever.
Conclusion: The MMR vaccine (Beijing) had good safety and immunogenicity which might be used to be the bases enhance immunization of measles.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Retrospective analysis in children with vaccination granuloma].
Dermatologie (Heidelb)
January 2025
Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University, München, Deutschland.
Background: Vaccine granulomas are a common (0.3-1%) adverse event (AE) of (accidentally) subcutaneously administered vaccines and specific immunotherapies containing aluminum conjugates. The clinical symptoms with persistent itching subcutaneous nodules, predominantly affect infants and young children on the lateral thigh.
View Article and Find Full Text PDFImmunisation schedule of the Pediatric Spanish Association: 2024 recommendations.
An Pediatr (Engl Ed)
January 2025
Pediatrician, Barcelona, Spain.
The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.
View Article and Find Full Text PDFNavigating vaccine confidence: A mixed methods study investigating healthcare providers' perspectives across four non-EU European regions.
Vaccine
January 2025
Universiteit Antwerpen, Antwerp, Belgium; London School of Hygiene & Tropical Medicine, London, UK. Electronic address:
Background: Vaccine confidence remains a global public health challenge, especially highlighted during the COVID-19 pandemic. Public trust in vaccines is crucial, with healthcare providers (HCPs) playing a pivotal role in navigating this sensitive topic. This requires an understanding of HCPs' perceptions of vaccines.
View Article and Find Full Text PDFThe Oncogenic Human Papillomavirus Involvement as a Risk Factor of Measles, Mumps, and Rubella Vaccine Immunotherapy Failure in Anogenital Warts.
Int Med Case Rep J
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, Indonesia.
Anogenital warts (AGW) including multiple types of human papillomavirus (HPV) are prevalent. In this context, oncogenic HPV infection leads to anogenital cancers and the lesion is more persistent. Several research on AGW therapy with measles, mumps, and rubella (MMR) vaccine injections have been successful without adverse effects.
View Article and Find Full Text PDFParental Factors Associated With Measles-Mumps-Rubella Vaccination in US Children Younger Than 5 Years.
Am J Public Health
January 2025
Eric Geng Zhou is with the Center for Child Health Services Research, Icahn School of Medicine at Mount Sinai, New York, NY. Jonathan Cantor is with RAND, Santa Monica, CA. Autumn Gertz, John S. Brownstein, and Benjamin Rader are with Innovation and Digital Health Accelerator, Boston Children's Hospital, Boston, MA. Brian Elbel is with the Department of Population Health, Grossman School of Medicine, New York University, New York.
To determine the association between parental characteristics and MMR (measles-mumps- rubella) vaccination status of children in the United States. We conducted a cross-sectional study from July 2023 to April 2024 using a digital health survey via OutbreaksNearMe, weighted to target national population characteristics. We analyzed the responses of 19 892 parents of children younger than 5 years to examine the association between self-reported parental characteristics (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!